1.56 -0.04 (-2.48%)
PARD
Stock Details
Last Trade:1.56 Change:-0.04 (-2.48%) Prev Close:1.60 Open: 1.61 Days Range:1.56 – 1.62 52 Week Range: 1.50 - 9.14 Volume:1536268 P/E: N/AEPS:-1.31
View AllRecent Alerts 03/21/10
Recent Alert on 03/08/10 at 8:05am
Poniard Pharmaceuticals, Inc. (PARD) Posts Q4 Loss of $0.36, Wider than Views
Poniard Pharmaceuticals, Inc. (PARD) Posts Q4 Loss of $0.36, Wider than Views
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) reports Q4 loss of $0.36, versus the analyst estimate of ($0.24).
Recent Alert on 03/05/10 at 3:33pm
Trading Radar for 03/08: Yingli Green Energy (YGE), H & R Block (HRB), TiVo (TIVO), Force Protection (FPRT) Report
Trading Radar for 03/08: Yingli Green Energy (YGE), H & R Block (HRB), TiVo (TIVO), Force Protection (FPRT) Report
Recent Alert on 02/03/10 at 12:34pm
Poniard Pharma (PARD) Names Martell as New CEO, Succeeding McMahon; to Reduce Workforce by 21 Employees
Poniard Pharma (PARD) Names Martell as New CEO, Succeeding McMahon; to Reduce Workforce by 21 Employees
Recent Alert on 02/03/10 at 12:34pm
Poniard Pharma (PARD) Names Martell as New CEO, Succeeding McMahon; to Reduce Workforce by 21 Employees
Poniard Pharma (PARD) Names Martell as New CEO, Succeeding McMahon; to Reduce Workforce by 21 Employees
View AllRecent Press Releases
Press Release on 03/18/10 at 1:30pm
U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter
U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 02/08/10 at 4:14am
GlaxoSmithKline, Poniard, Protalix Provide Biotech's Latest Mishaps
GlaxoSmithKline, Poniard, Protalix Provide Biotech's Latest Mishaps
Blog Posts on 01/25/10 at 11:45am
Analyst Upgrades, Downgrades and Initiations: GD, ICE, IGT, SAP, STI, TMH, TSS ...
Analyst Upgrades, Downgrades and Initiations: GD, ICE, IGT, SAP, STI, TMH, TSS ...
Blog Posts on 01/11/10 at 4:04am
Poniard Pharmaceuticals: Oversold, Undervalued, Poised for Short Squeeze
Poniard Pharmaceuticals: Oversold, Undervalued, Poised for Short Squeeze